Auerbach Michael, DeLoughery Thomas G, Tirnauer Jennifer S
Auerbach Hematology and Oncology, Baltimore, Maryland.
Georgetown University School of Medicine, Washington, DC.
JAMA. 2025 May 27;333(20):1813-1823. doi: 10.1001/jama.2025.0452.
Absolute iron deficiency, defined as low iron stores with or without anemia, affects approximately 2 billion people worldwide and 14% of adults in the US. Iron-deficiency anemia, defined as low hemoglobin due to low iron stores, affects approximately 1.2 billion people worldwide, including 10 million in the US.
Absolute iron deficiency progresses from low iron stores to iron-deficiency anemia. Individuals with nonanemic iron deficiency or iron-deficiency anemia may be asymptomatic or experience fatigue, irritability, depression, difficulty concentrating, restless legs syndrome (32%-40%), pica (40%-50%), dyspnea, lightheadedness, exercise intolerance, and worsening heart failure (HF). Symptom prevalences vary depending on age, comorbidities (eg, chronic kidney disease [CKD], HF), and severity and rate of development of iron deficiency. The most common causes of iron deficiency are bleeding (menstrual, gastrointestinal), impaired iron absorption (atrophic gastritis, celiac disease, bariatric surgical procedures), inadequate dietary iron intake, and pregnancy. In high-income countries, approximately 38% of nonpregnant, reproductive-age women have iron deficiency without anemia and about 13% have iron-deficiency anemia. During the third trimester of pregnancy, iron deficiency affects up to 84% of pregnant women, based on data from high-income countries. Additional risk factors include use of nonsteroidal anti-inflammatory drugs, inflammatory bowel disease (IBD [13%-90%]), and other chronic inflammatory conditions, such as CKD (24%-85%), HF (37%-61%), and cancer (18%-82%). Testing for iron deficiency is indicated for patients with anemia and/or symptoms of iron deficiency (fatigue, pica, or restless legs syndrome) and should be considered for those with risk factors such as heavy menstrual bleeding, pregnancy, or IBD. Iron deficiency is diagnosed by low serum ferritin (typically <30 ng/mL) in individuals without inflammatory conditions or by transferrin saturation (iron/total iron binding capacity × 100) less than 20%. Causes of iron deficiency should be identified and treated. Oral iron (ferrous sulfate 325 mg/d or on alternate days) is typically first-line therapy. Intravenous iron is indicated for patients with oral iron intolerance, poor absorption (celiac disease, post-bariatric surgical procedure), chronic inflammatory conditions (CKD, HF, IBD, cancer), ongoing blood loss, and during the second and third trimesters of pregnancy.
Iron deficiency and iron-deficiency anemia are common conditions that may cause symptoms such as fatigue, exercise intolerance, and difficulty concentrating. Ferritin and/or transferrin saturation are required for diagnosis and screening. Oral iron is first-line therapy for most patients. Intravenous iron is used for individuals who do not tolerate or have impaired absorption of oral iron, those with ongoing blood loss, certain chronic inflammatory conditions (IBD, CKD, HF, cancer), and during the second and third trimesters of pregnancy.
绝对缺铁定义为铁储备低,无论有无贫血,全球约有20亿人受其影响,在美国14%的成年人受其影响。缺铁性贫血定义为因铁储备低导致血红蛋白低,全球约有12亿人受其影响,其中美国有1000万人。
绝对缺铁从铁储备低发展为缺铁性贫血。非贫血性缺铁或缺铁性贫血患者可能无症状,或出现疲劳、易怒、抑郁、注意力不集中、不宁腿综合征(32%-40%)、异食癖(40%-50%)、呼吸困难、头晕、运动不耐受以及心力衰竭加重。症状发生率因年龄、合并症(如慢性肾脏病[CKD]、心力衰竭)以及缺铁的严重程度和发展速度而异。缺铁最常见的原因是出血(月经、胃肠道)、铁吸收受损(萎缩性胃炎、乳糜泻、减肥手术)、饮食中铁摄入不足以及妊娠。在高收入国家,约38%的非妊娠育龄妇女缺铁但无贫血,约13%患有缺铁性贫血。根据高收入国家的数据,在妊娠晚期,高达84%的孕妇缺铁。其他风险因素包括使用非甾体抗炎药、炎症性肠病(IBD[13%-90%])以及其他慢性炎症性疾病,如CKD(24%-85%)、心力衰竭(37%-61%)和癌症(18%-82%)。对于贫血和/或有缺铁症状(疲劳、异食癖或不宁腿综合征)的患者,应进行缺铁检测,对于有月经过多、妊娠或IBD等风险因素的患者也应考虑检测。在无炎症的个体中,血清铁蛋白低(通常<30 ng/mL)或转铁蛋白饱和度(铁/总铁结合力×100)低于20%可诊断缺铁。应确定并治疗缺铁的原因。口服铁剂(硫酸亚铁325 mg/d或隔日服用)通常是一线治疗方法。静脉铁剂适用于口服铁剂不耐受、吸收不良(乳糜泻、减肥手术后)、慢性炎症性疾病(CKD、心力衰竭、IBD(炎症性肠病)、癌症)、持续失血以及妊娠第二和第三孕期的患者。
缺铁和缺铁性贫血是常见病症,可能导致疲劳、运动不耐受和注意力不集中等症状。诊断和筛查需要铁蛋白和/或转铁蛋白饱和度检测。口服铁剂是大多数患者的一线治疗方法。静脉铁剂用于不耐受口服铁剂或口服铁剂吸收受损、有持续失血、某些慢性炎症性疾病(IBD、CKD、心力衰竭、癌症)以及妊娠第二和第三孕期 的患者。